Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
Information source: Hamamatsu University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia; Negative Symptoms; Cognitive Impairments
Intervention: Pergolide (drug) (Drug)
Phase: Phase 2
Status: Suspended
Sponsored by: Hamamatsu University Official(s) and/or principal investigator(s): Norio Mori, Ph.D, Study Chair, Affiliation: Hamamatsu University, School of Medicine, Department of Psychiatry and Neurology
Summary
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower
dopaminergic activity is associated with negative symptoms and cognitive dysfunction
observed in the patients of schizophrenia is of a heuristic value in guiding research in
this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve
negative symptoms and cognitive impairments prevailing in most patients with schizophrenia.
This double-blind placebo controlled study will investigate the remedial effect of pergolide
on negative symptoms and cognitive impairments in schizophrenia.
Clinical Details
Official title: Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia
Study design: Observational Model: Defined Population, Time Perspective: Cross-Sectional
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Patients
- Were age 18–50 years, met the DSM-IV criteria for schizophrenia
- Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8
weeks
- Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale
(PANSS)
- Had a minimum period of symptom stability, defined as no more than 20% change on
consecutive ratings on PANSS for at lease 4 weeks
Exclusion Criteria:
- Had a history of medical condition or drug treatment that may have affected cognitive
performance
- Had a history of other psychiatric disorders
Locations and Contacts
Hamamatsu University Hospital, Hamamatsu, Shizuoka 431-3192, Japan
Additional Information
Related publications: Kimberg DY, D'Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia. 2003;41(8):1020-7. Müller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci. 1998 Apr 1;18(7):2720-8. Wang M, Vijayraghavan S, Goldman-Rakic PS. Selective D2 receptor actions on the functional circuitry of working memory. Science. 2004 Feb 6;303(5659):853-6. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004 Jun;174(1):3-16. Epub 2004 Apr 30. Review.
Starting date: March 2003
Last updated: September 13, 2005
|